Nuclear medicine in neurology and psychiatry

Lancet

Volumn 354, Issue 9184, 1999, Pages 1107-1111

  Costa, Durval C ^a   Pilowsky, Lyn S ^b   Ell, Peter J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR; DOPAMINE RECEPTOR; GLUCOSE; LIGAND; OXYGEN; SEROTONIN RECEPTOR;

BLOOD BRAIN BARRIER; BLOOD FLOW; HUMAN; NEUROLOGY; NEUROTRANSMISSION; NUCLEAR MEDICINE; PRIORITY JOURNAL; PSYCHIATRY; RADIATION DETECTOR; REVIEW;

EID: 0033604028     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)06095-X     Document Type: Review

References (44)

1. Masdeu J.C., Brass L.M., Holman B.L., Kushner M.J. Brain single-photon emission computed tomography. Neurology. 44:1994;1970-1977.
2. Raichle M.E. Imaging the mind. Sem Nucl Med. 28:1998;279-289.
3. Mountz J.M., Modell J.G., Foster N.L.et al. Prognostication of recovery following stroke using the comparison of CT and Technetium-99m HM-PAO SPECT. J Nucl Med. 31:1990;61-66.
4. Barber P.A., Davis S.M., Infeld B.et al. Spontaneous reperfusion after ischemic stroke is associated with improved outcome. Stroke. 29:1998;2522-2528.
5. Giubilei F., Lenzi G.L., Di Piero V.et al. Predictive value of brain perfusion single-photon emission computed tomography in acute ischemic stroke. Stroke. 21:1990;895-900.
6. Marchal G., Beaudouin V., Rioux P.et al. PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet. 341:1993;925-927.
7. Burt R.W., Witt R.M., Cikrit D.F., Reddy R.V. Carotid artery disease: evaluation with acetazolamide-enhanced Tc-99m HMPAO SPECT. Radiology. 182:1992;461-466.
8. Owens J., Wyper D.J., Patterson J.et al. First SPET images of glutamate (NMDA) receptor activation in vivo in cerebral ischaemia. Nucl Med Commun. 18:1997;149-158.
9. Costa D.C., Motteux I.M., McCready A.C. Diagnosis of brain death with technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med. 18:1991;503-506.
10. 99mTc-HMPAO SPECT in the diagnosis of brain death. Intensive Care Med. 24:1998;911-917.
11. 99mTc-HMPAO SPECT studies in traumatic intracerebral haematoma. J Neurol Neurosurg Psychiatry. 54:1991;6-11.
12. Garada B., Klufas R.A., Schwartz R.B. Neuroimaging in closed head injury. Semin Clin Neuropsychiatry. 2:1997;188-195.
13. Otte A., Mueller-Brand J., Fierz L. Brain SPECT findings in late whiplash syndrome. Lancet. 345:1995;1513-1514.
14. Gilman S. Advances in neurology II. N Engl J Med. 326:1992;1671-1676.
15. Rowe C.C., Berkovic S.F., Austin M.C.et al. Patterns of postictal cerebral blood flow in temporal lobe epilepsy: qualitative and quantitative analysis. Neurology. 41:1991;1096-1103.
16. Ward A.A. Perspectives for surgical therapy of epilepsy. Ward A.A., Penry J.K., Walter R.D. ARNMD 61. 1983;371-390 Raven, New York.
17. Shorvon S.D. Medical services for epilpsy. Richens A., Laidlaw J., Oxley J. A textbook of epilepsy, 3rd ed. 1988;611-630 Churchill Livingstone, Edinburgh.
18. Erkinjuntti T., Ostbye T., Steenhuis R., Hatchinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med. 337:1997;1667-1674.
19. Skoog I., Marcusson J., Blennow K. It's getting better all the time. Lancet. 352:1998;4. (suppl IV).
20. Buttler C.R.E., Costa D.C., Walker Z. Katona CLE, PET and SPECT imaging in the dementias. Murray I.P.C., Ell P.J. Nuclear medicine in clinical diagnosis and treatment, 2nd ed. 1998;713-728 Churchill Livingstone, Edinburgh.
21. Jobst K.A., Smith A.D., Barker C.S.et al. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological dignosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 55:1992;190-194.
22. Goodwin G.M. Functional imaging, affective disorder and dementia. Br Med Bull. 52:1996;495-512.
23. Schapira A.H.V. Parkinson's disease. BMJ. 318:1999;311-314.
24. 123I in humans. Eur J Nucl Med. 16:1990;813-816.
25. Walker Z., Costa D.C., Janssen A.G.et al. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med. 24:1997;609-614.
26. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology. 42(3):1992;556-561.
27. Costa D.C., Walker Z., Walker R.W.H.et al. Dementia with Lewy bodies: preliminary data on clinical, pathological and FP-CIT SPET correlations. Nucl Med Commun. 20:1999;467-468.
28. Miller R.F., Hall-Craggs M.A., Costa D.C.et al. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for the discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect. 74:1998;258-264.
29. 18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med. 26:1999;144-151.
30. Shields A.F., Grierson J.R., Dohmen B.M.et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 4:1998;1334-1336.
31. Peroutka S.J., Snyder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histaminergic receptors to clinical potency. Am J Psychiatry. 137:1980;1518-1522.
32. Farde L., Wiesel A., Nordstrom A.L.et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacol (Berl). 99:1989;28-31.
33. Pilowsky L.S., Costa D.C., Ell P.J.et al. Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet. 340:1992;199-202.
34. Farde L., Nordstrom A.L., Wiesel A.et al. Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Arch Gen Psychiatry. 49:1992;538-543.
35. Nordstrom A.L., Farde L., Weisel F.A.et al. Central D2 dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study of schizophrenic patients. Biol Psychiatry. 33:1993;227-235.
36. Pilowsky L.S., Mulligan R., Acton P., Costa D.et al. Limbic selectivity of clozapine. Lancet. 350:1997;490-491.
37. Travis M.J., Busatto G.F., Pilowsky L.S.et al. Serotonin 5-HT2a occupancy in vivo and response to the new antipsychotics olanzapine and sertindole. Br J Psychiatry. 171:1997;290-291.
38. Trichard C., Paillere-Martinot M.L., Attar-Levy D.et al. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry. 155:1998;505-508.
39. Seibyl J.P., Marek K., Sheff K.et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 39:1998;1500-1508.
40. Ruottinen H., Rinne J.O., Laihinen A.et al. The effect of COMT inhibition with entacapone on 18F-6-fluorodopa PET in Parkinson's disease. J Cereb Blood Flow Metab. 13:1993;359.
41. Brooks D. PET: its clinical role in neurology. J Neurol Neurosurg Psychiatry. 54:1991;1-5.
42. Volkow ND Wang GJ, Fischman MW et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 386:1997;827-830.
43. Volkow N.D., Wang G.J., Fowler J.S.et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high" J Pharmacol Exp Ther. 288:1999;14-20.
44. Dewey S.L., Morgan A.E., Ashby C.R. Jret al. A novel strategy for the treatment of cocaine addiction. Synapse. 30:1998;119-129.